Mayo Clinic collaborates to advance Crohn's treatment A study led by Mayo Clinic has found that infliximab (Remicade®) administered alone (monotherapy) or in combination with azathioprine is a more effective treatment for patients with moderate to severe Crohn's disease than azathioprine alone. view more (2008-10-06)
Government money for multiple sclerosis patients could be better spent The National Institute for Clinical Excellence (NICE) has announced that neither interferon beta nor glatiramer can be recommended for multiple sclerosis in the NHS. However, the UK government plans to make these drugs available through a risk sharing scheme, despite limited evidence of clinical and cost effectiveness. Researchers in this week's... view more... (2003-02-12)
Predictors of disease behavior change in Crohn's disease Using the Vienna classification system, it has been shown in clinic-based cohorts that there can be a significant change in disease behavior over time, whereas disease location remains relatively stable. view more (2009-08-10)
Treatment of kidney condition requires an individualised Good patient information is essential for choosing the best treatment for the kidney disease lupus nephritis. Dutch researcher Cecile Grootscholten concludes this following her doctoral research into two methods for treating lupus nephritis. view more (2007-05-15)
Role for proteomics in identifying hematologic malignancies Scientists have identified a set of biomarkers that could help clinicians identify a group of hematologic malignancies known as myelodysplastic syndromes (MDS), which affect approximately 300,000 individuals worldwide and often progress to acute myeloid leukemia. view more (2007-01-11)
